Story

Annexon Shares Fall on Clinical Trial Change and Q2 Earnings Miss

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Annexon Shares Fall on Clinical Trial Change and Q2 Earnings Miss
Text size
Background

Shares of Annexon (NASDAQ: ANNX) fell sharply in pre-market trading after the company announced a wider-than-expected second-quarter loss and a significant amendment to a late-stage clinical trial for its lead drug candidate. The stock was down 5.9% in pre-open trading as investors reacted to the dual pieces of negative news.

Dual Disappointments Pressure Shares

Annexon reported a net loss of $0.28 per share for the second quarter of 2026, missing the Wall Street consensus estimate of a $0.24 per-share loss. The total net loss attributable to common stockholders grew to $55.3 million from $51.0 million in the same period a year prior, according to the company's earnings release.

Compounding the financial miss, Annexon also disclosed an amendment to its Phase 3 ARCHER II trial for vonaprument, a treatment for dry age-related macular degeneration. The key changes include:

  • Addition of a month 24 co-primary endpoint.
  • The study can now meet its primary objective at either the original month 15 or the new month 24 assessment.
  • Topline data from the month 15 timepoint is anticipated in the fourth quarter of 2026.

Market Interprets Trial Change as a Negative Signal

Sample IUX Markets – In-articleAd

In the biopharmaceutical industry, the addition of a later primary endpoint to a clinical trial is often interpreted by investors as a potential sign of weakness in the earlier data. The structural change to the ARCHER II trial raises concerns about whether the month 15 data alone will be sufficient to demonstrate a clear efficacy signal for vonaprument.

This amendment extends the period of uncertainty for investors awaiting a definitive verdict on the company's most advanced asset. The company's research and development expenses also rose to $46.6 million for the quarter, largely reflecting the costs of the ARCHER II program.

Company-Specific News Drives Decline

The sell-off in Annexon stock appeared to be driven by its own news rather than broader market sentiment. During the same pre-market session, the S&P 500 and Nasdaq were trading higher following the release of the July 2026 Consumer Price Index report. The absence of significant selling pressure across the wider biotechnology sector underscored that Annexon's decline was a reaction to its specific clinical and financial updates.

Read next

More on Stocks
Back to latest news

LATEST